Lantern Pharma launches ZetaOmics, an AI-powered computational biology module of its withZeta.ai platform, automating multi-omic analysis to accelerate cancer research and drug development.
This matters because ZetaOmics represents a leap forward in democratizing advanced bioinformatics. By automating complex multi-omic analyses with an AI co-scientist, it could significantly accelerate cancer research, reduce costs, and improve reproducibility—benefiting researchers, clinicians, and ultimately patients by speeding up the discovery of new therapies.
